Navigation Links
NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir

A pre-grant opposition has been filed against the anti-HIV drug, Combivir, manufactured by GlaxoSmithKline, a leading pharmaceutical company //. The Manipur Network of Positive People (MNP+) and the Indian Network of People Living with HIV/AIDS have lodged the complaint at the Kolkata patent office.

The drug formulation is a combination of two essential anti-HIV drugs Lamivudine and Zidovudine and is not a new formulation, said a release. The grant of a patent is believed to make the anti-retroviral treatment expensive for patients afflicted with the deadly disease.

'We are objecting to the patenting of Combivir because it is not a new invention but simply the combination of two existing drugs,' said K K Abraham, president, INP+.

A similar opposition was raised regarding patenting anti-cancer drug, Gleevac, manufactured by Novartis. The patent was turned down subsequently as it was found to nothing more than a new form of an old drug.

Combivir is one of the anti-retroviral drugs used by numerous AIDS/HIV organizations, worldwide. A fixed dose combination of the drug is used in several projects targeted at provision of cheap and effective AIDS/HIV treatment to those who cannot afford the same.

In India, more than 5.1 million people are afflicted with AIDS/HIV and a majority of these are solely dependent on the generic drugs provided by the national HIV/AIDS treatment program. The issue of a patent can lead to domination with respect to drug manufacture, thereby restricting the production of effective and affordable drug alternatives.


'"/>




Page: 1

Related medicine news :

1. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
2. Venus Remedies Files 5th International Patent Application
3. AIIMS Official Files Complaint Against Venugopal
4. Glaxo Files Cancer Drug For Approval With FDA
5. Queensland Opposition not happy over hiring consultancy
6. Opposition: Government turned a deaf ear to warnings about dwindling health care services
7. Kleins Third Way Has Tough Opposition
8. Opposition to Compulsory Fortification of Bread with Folic Acid
9. Opposition against Amendments in the Intellectual Property Law
10. Madhya Pradesh Begins Surya Namaskar Amid Muslim Opposition
11. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... ... , ... Harris Communications, Inc., a leading provider of assistive technology for ... Deaf Seniors of America Conference, April 4-7 at the Hotel Westin Galleria in Houston. ... staff from Harris Communications and to try out the newest assistive devices available to ...
(Date:3/25/2017)... ... , ... Getting earned media coverage meaningful for Garden Media Group's clients is ... year, Garden Media aims to provide material helpful to clients’ goals and bottom lines. ... key messages to gain coveted media placements, Garden Media wows clients year-round. , ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... solutions for contaminated soil, dredged material, and hazardous and non-hazardous materials announced today ... Allentown, Pennsylvania. This acquisition will add four additional processing facilities and a ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today ... conversation on the current obstacles facing infection prevention and offer strategies for the ... by these infections. , The print component of “Fighting Infection” is distributed ...
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software innovation lab specializing in ... a Greenville, South Carolina location. The lab has set up shop at ... been working with South Carolina clients for years from our office here in Atlanta,” ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , March 27, ... global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: ... and commercialization of innovative therapies based upon tetracycline ... of sarecycline for the treatment of moderate to ... endpoints. Sarecycline is a once-daily, oral, narrow spectrum ...
(Date:3/27/2017)... 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), a ... liver diseases in children, today reported financial results ... December 31, 2016 and provided an update on ... to make progress during the fourth quarter of ... our non-human primate safety study, and with our lead ...
(Date:3/24/2017)... , Mar 24, 2017 Research ... Therapy Manufacturing Market, 2017-2027" report to their offering. ... The Cell ... the rapidly growing market of cell therapy manufacturing and focuses ... manufacturing facilities. These therapies are anticipated to emerge as viable ...
Breaking Medicine Technology: